# Tutorial for variant interrogation in tumor samples

**Authors:** Riley J. Arseneau, Leah K. MacLean, Jeanette E. Boudreau, Daniel Gaston

PMC · DOI: 10.1371/journal.pcbi.1013924 · PLOS Computational Biology · 2026-02-17

## TL;DR

This paper provides a step-by-step guide to help researchers analyze genetic mutations in cancer samples using next-generation sequencing.

## Contribution

The paper introduces a practical, accessible framework for variant analysis in tumor samples, emphasizing reproducibility and clinical relevance.

## Key findings

- The framework is structured into four phases: Planning, Gathering Resources, Filtering and Validation, and Dissemination and Storage.
- It emphasizes the importance of reproducibility and transparency in variant analysis for translational research.
- The guide is designed to lower the barrier for researchers new to the field of somatic mutation analysis.

## Abstract

The increasing accessibility of next-generation sequencing has empowered researchers to investigate somatic mutations in cancer. The complexity of variant analysis pipelines, terminology, and tool selection remains a major barrier, especially for those new to the field or working in translational settings. To address this challenge, we present a practical framework that guides researchers through the critical steps of variant interrogation in tumor samples. This guide is broken into four phases: Planning—laying the foundation for thoughtful experimental design and a clear understanding of sequencing outputs; Gathering Resources—assembling the tools, reference data, and variant annotation sets required for analysis; Filtering and Validation—executing a systematic approach to prioritize meaningful variants; and Dissemination and Storage—ensuring findings are reproducible and accessible through transparent reporting and data sharing. Developed with an emphasis on accessibility, reproducibility, and clinical relevance, this framework equips researchers with the guidance to navigate variant analysis with confidence and rigor.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** BIN1 (bridging integrator 1) [NCBI Gene 274] {aka AMPH2, AMPHL, CNM2, SH3P9}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, BIN2 (bridging integrator 2) [NCBI Gene 51411] {aka BRAP-1}, BIN3 (bridging integrator 3) [NCBI Gene 55909]
- **Diseases:** CNV (MESH:D000092342), REFERENCE_ACCESSION (MESH:D053591), BAM (MESH:C535477), HGVS (MESH:C000719191), TRANSCRIPT_ACCESSION (OMIM:602482), compression (MESH:D009408), Tumor (MESH:D009369), VAF (MESH:D006316), VCF (MESH:D058426)
- **Chemicals:** BAM (-), formalin (MESH:D005557), paraffin (MESH:D010232), cytosine (MESH:D003596)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** G12V, c.34G > T, C > T
- **Cell lines:** FLAG — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_C0IU)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12912624/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12912624/full.md

## References

116 references — full list in the complete paper: https://tomesphere.com/paper/PMC12912624/full.md

---
Source: https://tomesphere.com/paper/PMC12912624